GSK:LON
GSK plc
1Â 773,00Â GBX
arrow_downward
−0,98%(−17,50) 1 p
8. okt, 17:15:00 GMT +1 · GBX
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse GSK põhistatistika genereerimine…
Ava
1Â 773,00Â GBX
Kõrge
1Â 773,00Â GBX
Madal
1Â 735,50Â GBX
Turu kapit.
94,29Â mld
Keskm. maht
5,51Â mln
Maht
16,33Â mln
Dividend
3,84%
Kvartaalne dividend
17,00Â GBX
Dividendikuupäev
13. aug 2026
Hinna ja tulu suhe
15,03
52 näd kõrgeim
2Â 282,00Â GBX
52 näd madalaim
1Â 592,00Â GBX
Aktsiatulu
1,18Â GBX
Käibivad aktsiad
4,32Â mld
Töötajate arv
67Â tuh
Ava
1Â 773,00Â GBX
Kõrge
1Â 773,00Â GBX
Madal
1Â 735,50Â GBX
Turu kapit.
94,29Â mld
Keskm. maht
5,51Â mln
Maht
16,33Â mln
Dividend
3,84%
Kvartaalne dividend
17,00Â GBX
Dividendikuupäev
13. aug 2026
Hinna ja tulu suhe
15,03
52 näd kõrgeim
2Â 282,00Â GBX
52 näd madalaim
1Â 592,00Â GBX
Aktsiatulu
1,18Â GBX
Käibivad aktsiad
4,32Â mld
Töötajate arv
67Â tuh
Uudised
Veebiallikatest ja uudistepartneritelt
AD HOC NEWS
·
5 tunni eest
GSK launches shingles campaign: stock after-hours at EUR 20.55, down 2.10 percent
TipRanks
·
7 tunni eest
GSK Director Wendy Becker Joins Tesco Board as Non-Executive
Financial-News.co.uk
·
9 tunni eest
GSK Passive Income Stock Draws ISA Buyers Despite Cost-Savings Push
Stock Titan
·
10 tunni eest
Viola Davis says shingles pain was 9 out of 10. She couldn't work.
Profiil
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
Teave üksuse GSK plc kohta
TegevjuhtEmma Walmsley | Emma Walmsley
Töötajad66,8 tuh
Asutatud27. dets 2000
Peakontorid-
Sektor-
Veebisaitgsk.com